Health
Diabetes: Colexa Biosensor Manufactures Blood Glucose Meters, Strips
By Modupe Gbadeyanka
A subsidiary of Codix Pharma Limited, Colexa Biosensor Limited, is now producing blood glucose meters and strips, which have been duly evaluated, approved, and registered by the National Agency for Food and Drugs Administration and Control (NAFDAC).
This flagship product addresses the prevalence of diabetes in Africa affecting millions of people living with the disease, as it would assist in early detection and management to aid recovery and wellness.
Speaking at the commissioning of its In-Vitro Diagnostics (IVD) factory in Lagos, the chairman of Colexa Biosensor Limited, Mr Sammy Ogunjimi, said with the firm’s focus on Africa and with Nigeria as its base, it aims to extend its solution throughout Africa and the world and contribute its efforts to correcting the deficit in the balance of trade and to raising the volume of exports to improve the foreign exchange situation.
“We aim to localize and backwards integrate to reduce our dependence on imports and this factory is the first step towards achieving that goal.
“As a testament to our utmost desire to ensure consistent product and service quality, we are happy to announce that this factory has received 2 Quality Management System certifications – 1st the ISO 13485:2016 (IVD) Certificate, and the ISO 9001: 2015 (process) certificate.
“We have also received a successful independent comparative evaluation of OnPoint BGM with the market gold standard through the Medical Laboratory Science Council of Nigeria (MLSCN). Colexa Biosensor Limited will provide direct employment for over 700 staff and several more indirectly,” he stated.
The facility, with an installed capacity of 3.6 million packs and an opportunity to scale up to 10.8 million packs annually, is poised to meet local demand and export, starting with its subsidiaries across West Africa, with the added advantage of reducing the need for foreign exchange in procuring raw materials.
In his keynote address, the Coordinating Minister of Health and Social Welfare, Professor Muhammad Ali Pate, reiterated the commitment of the federal government to patronize local manufacturers of healthcare products and ensure the prevention of spending the country’s short supply of foreign exchange on importation of pharmaceutical products that can be produced locally.
“Our President, Mr Bola Tinubu, sees it as unacceptable that 99 per cent of medical devices and more than 70 per cent of our generic pharmaceutical equipment in Nigeria are imported.
“The federal government will purchase locally manufactured diabetes test kits because we know that diabetes is a very significant cause of morbidity in our country.
“We are committed to developing our healthcare industry to contribute to the African healthcare market by providing the critical commodities and services that will optimize the health of our populations, ensure our health security and retain all the economic value in our country,” the Minister said.
Speaking earlier, the Chairman of the occasion, Mr Julius Adewale Adelusi-Adeluyi, a former Minister of Health, urged the government to ensure an environment that enables companies like Colexa Biosensor to thrive and remain sustainable.
In her goodwill message, the Director General of NAFDAC, Mrs Mojisola Adeyeye, hailed Sammy Ogunjimi and Lekan Asuni for their vision of ensuring that the country can meet its local consumption of IVD products.
Health
Helical Secures $10m Funding Package for Expansion
By Dipo Olowookere
A $10 million capital has been raised by Helical to support expansion across more top-20 pharma programmes and growth of its deployed science engineering team.
The firm will also use the money to build the compounding evidence layer that improves performance across diseases, as its mission is to make every scientist able to test hypotheses at the speed of inference and to turn in-silico discovery into a reliable engine for R&D throughput.
The funding package was from redalpine, Gradient, BoxGroup, Frst and notable angels, including Aidan Gomez (CEO Cohere), Clement Delangue (CEO HuggingFace) and Mario Goetze (pro soccer player).
Helical has a product known as the virtual AI lab for pharma, an application layer that turns biological foundation models into decision-ready, reproducible in-silico discovery workflows.
The platform has two product surfaces — the Virtual Lab for biologists and translational scientists, and the Model Factory for ML engineers and data scientists — built on the same data, the same models, and the same results.
By putting both sides in the same system, Helical closes the gap between computational predictions and biological decision-making, so teams that traditionally worked in silos can collaborate on the same evidence.
Helical was founded in early 2024. It was created by three school friends who took different paths to the same problem.
Rick Schneider built tech at Amazon and later helped the German enterprise Celonis scale in France and Japan. Maxime Allard led data science teams at IBM before pursuing a PhD focused on reinforcement learning and robotics. Mathieu Klop became a cardiologist and genomics researcher.
When bio foundation models emerged, the trio saw the chance to build the missing application layer that would let pharma teams move from model experimentation to reproducible, production discovery.
“The models alone don’t discover drugs. The system does. Pharma teams need a system that turns foundation models into workflows scientists can run, validate, and defend.
“We built Helical to make in-silico science reproducible at pharma scale, so teams can go from hypothesis to decision in days instead of months,” the co-founder of Helical, Mr Rick Schneider, said.
“We are at a unique point in time where biological foundation models and general language reasoning models are converging.
“We backed Helical because we strongly believe they have what it takes to build the pharma AI orchestration platform that will drive this transition from siloed AI models to integrated virtual AI labs,” the General Partner at redalpine, Mr Daniel Graf, stated.
Health
NARD Suspends Indefinite Strike, Gives FG Fresh Two-Week Ultimatum
By Adedapo Adesanya
The Nigerian Association of Resident Doctors (NARD) has suspended its planned nationwide indefinite strike, granting the federal government a two-week ultimatum to address lingering welfare issues affecting resident doctors across the country.
The decision was taken after an emergency meeting of the association’s National Executive Council on Tuesday, where members reviewed assurances from government representatives and resolved to give dialogue another chance.
NARD said the suspension was informed by “progress made” in negotiations, particularly commitments on the prompt payment of salary arrears, hazard allowances, and steps toward resolving issues surrounding the Medical Residency Training Fund.
The association did not declare a full resolution of the dispute. It noted that the government had shown “renewed willingness” to address the concerns that triggered the strike threat.
The association noted that while these engagements signalled a willingness by the government to resolve the dispute, several critical issues remain outstanding, particularly the delayed payment of promotion arrears, salary arrears, the 2026 Medical Residency Training Fund (MRTF), and the backlog of 19 months’ professional allowance arrears owed to resident doctors.
It also expressed concern over the Federal Government’s decision to halt the implementation of the reviewed PAT, which had earlier triggered widespread dissatisfaction among its members and raised fears of disruption to healthcare services nationwide.
Despite these unresolved issues, NARD said it opted to suspend the strike as a demonstration of goodwill and commitment to ongoing dialogue, while giving the government a two-week window to take concrete, measurable and verifiable steps to meet its demands.
The association insisted on the immediate reversal of the decision affecting the PAT, payment of all outstanding arrears, prompt disbursement of the MRTF, and full settlement of the accumulated professional allowance backlog.
It warned that it would reconvene at the expiration of the ultimatum to assess the level of compliance and determine its next course of action, adding that failure by the government to meet its demands within the stipulated timeframe would result in the resumption of the suspended strike without further notice.
NARD also called on its members nationwide to remain calm, united and resolute, while urging the Federal Government to act swiftly to prevent a potential crisis in the health sector.
The association further appreciated the interventions of the Vice President and other stakeholders, expressing hope that their involvement would lead to the timely resolution of the dispute and help sustain healthcare delivery across the country.
Health
Jacaranda Gets Funds to Expand Affordable Maternal Healthcare in Kenya
By Modupe Gbadeyanka
To expand affordable healthcare in Kenya, Swedfund has invested about $600,000 into Jacaranda Health Limited (Jacaranda Maternity) to support innovations in neonatal intensive care and strengthen Jacaranda’s ability to provide life-saving services to underserved populations.
Jacaranda Maternity provides high-quality maternal health care at more affordable pricing than typical private providers, focusing on women in Nairobi’s low- and middle-income communities.
The new funding will support the opening of new hospitals, upgrading of neonatal care, and improvements to existing facilities.
Maternal and newborn health outcomes in Kenya remain a challenge, with maternal mortality still high despite improvements in skilled birth attendance.
Public health facilities play a central role but face capacity constraints, while access to reliable, quality care varies across regions and income groups.
Private healthcare providers offering essential maternity services at accessible price points can complement public provision.
Jacaranda Maternity aims to expand its network to six hospitals to achieve financial sustainability while scaling its impact. The healthcare provider is a recognised leader in promoting women’s health, with 71 percent of its staff being women, and a track record of effective environmental and social management.
“This investment will help Jacaranda Maternity provide life-saving care to more women and families while furthering Swedfund’s mission to promote inclusive and sustainable healthcare,” a Senior Investment Manager at Swedfund, Audrey Obara, said.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn
